Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Synthetic

5F-ADB-PINACA

A fluorinated indazole carboxamide with a tert-leucinamide chain, the most potent at CB1 in its series, classified as a narcotic in France.

Narcotic: named in schedule
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₁₉H₂₇FN₄O₂

CAS 1863065-90-0

Family
Synthetic CB receptor agonistNew psychoactive substance
Molar mass
362.40 g/mol

Updated on

In plain terms

5F-ADB-PINACA is a synthetic cannabinoid made in a laboratory. It does not exist in hemp and has nothing to do with cannabidiol. In laboratory assays it is the most potent of its series of eight compounds at the CB1 receptor, and it is classified as a narcotic in France.

Receptors and activity

Target network

CB1AgonistEC50 = 0.2 nM · not specified in the abstractfluorometric membrane potential assay; value inferred from the lower bound of the series (0.24 to 21 nM), 5F-ADB-PINACA being the most potent at CB1
  • Activates

The lower the cited value, the closer the target sits to 5F-ADB-PINACA: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 5F-ADB-PINACA.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1AgonistEC50 = 0.2 nM · not specified in the abstract94 out of 100

    Banister et al. 2015, ACS Chem Neurosci (new tab) · fluorometric membrane potential assay; value inferred from the lower bound of the series (0.24 to 21 nM), 5F-ADB-PINACA being the most potent at CB1

  2. CB2Agonistno measured value cited

    High-potency agonist at CB2; the series measured ranges from 0.88 to 15 nM, with no individual value found for this compound (Banister et al. 2015)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

5F-ADB-PINACA is, at the CB1 receptor, the most potent compound of a series that Banister et al. characterised in 2015: these indole and indazole carboxamides were arriving in growing numbers in forensic laboratories, associated with serious adverse effects, with no known pharmacology. All the compounds synthesised act as high-potency agonists (EC50 from 0.24 to 21 nM at CB1 and from 0.88 to 15 nM at CB2), and 5F-ADB-PINACA has the highest potency at CB1. A nomenclature precaution is needed: the terminal function here is a primary amide, whereas the corresponding methyl-ester compound, 5F-MDMB-PINACA, circulates under the name 5F-ADB. Carlier et al. (2017) describe 5F-ADB-PINACA and its non-fluorinated analogue ADB-PINACA as among the most potent synthetic cannabinoids tested to date, with several cases of severe intoxication; in human hepatocytes they identified 12 major metabolites for 5F-ADB-PINACA, oxidative defluorination followed by carboxylation being the main reaction. In mice, tolerance to hypothermia and rimonabant-precipitated withdrawal are much weaker than with JWH-018 (Wilson et al. 2022). No controlled study in human beings was found.

Key sources.

History

Source
A wholly synthetic molecule, absent from hemp and from every living organism. It is one of the indole and indazole carboxamides with a valinamide or tert-leucinamide side chain that forensic laboratories and law enforcement were meeting with increasing frequency, associated with serious adverse effects, although most were unprecedented in the scientific literature at the time of their discovery (Banister et al. 2015). None of this has anything to do with hemp or with cannabidiol products.

Origin

Laboratory synthesis

No known biosynthetic pathway: the molecule is produced by no plant and no living organism. It is entirely synthetic in origin and belongs to the chemical family of the tert-leucinamide-headed indazole-3-carboxamides.

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

indazole-3-carboxamide

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

5F-ADB-PINACA (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci. 2015;6(9):1546-1559 (new tab)PMID 26134475
  2. Carlier J, Diao X, Scheidweiler KB, Huestis MA. Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. Clin Chem. 2017;63(5):1008-1021 (new tab)PMID 28302730
  3. Markham J, Sparkes E, Boyd R, Chen S, Manning JJ, Finlay D et al. Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. ACS Chem Neurosci. 2022;13(8):1281-1295 (new tab)PMID 35404067
  4. Wilson CD, Hiranita T, Fantegrossi WE. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal. Drug Alcohol Depend. 2022;236:109468 (new tab)PMID 35643039
  5. Council Framework Decision 2004/757/JHA, consolidated version of 12.01.2026 (annex: substances subject to Union control) (new tab)

Identifiers

Names

IUPAC name
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide

Identifiers

Formula
C₁₉H₂₇FN₄O₂
CAS
1863065-90-0
PubChem CID
119058050(new tab)
InChIKey
SOYDDJYBRCNNIT-UHFFFAOYSA-N
SMILES
CC(C)(C)C(C(=O)N)NC(=O)C1=NN(C2=CC=CC=C21)CCCCCF

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.